96 related articles for article (PubMed ID: 24083570)
1. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
Somasundaram S; Anand RS; Venkatesan P; Paramasivan CN
BMC Microbiol; 2013 Oct; 13():218. PubMed ID: 24083570
[TBL] [Abstract][Full Text] [Related]
2. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE
Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
[TBL] [Abstract][Full Text] [Related]
5. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
Lee BM; Harold LK; Almeida DV; Afriat-Jurnou L; Aung HL; Forde BM; Hards K; Pidot SJ; Ahmed FH; Mohamed AE; Taylor MC; West NP; Stinear TP; Greening C; Beatson SA; Nuermberger EL; Cook GM; Jackson CJ
PLoS Pathog; 2020 Feb; 16(2):e1008287. PubMed ID: 32032366
[TBL] [Abstract][Full Text] [Related]
6. DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs.
Paoli-Lombardo R; Primas N; Vanelle P
Eur J Med Chem; 2024 Aug; 274():116559. PubMed ID: 38850856
[TBL] [Abstract][Full Text] [Related]
7. 2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F
Jian Y; Forbes HE; Hulpia F; Risseeuw MDP; Caljon G; Munier-Lehmann H; Boshoff HIM; Van Calenbergh S
J Med Chem; 2021 Jan; 64(1):440-457. PubMed ID: 33347317
[TBL] [Abstract][Full Text] [Related]
8. A novel molecule with notable activity against multi-drug resistant tuberculosis.
Nair V; Okello MO; Mangu NK; Seo BI; Gund MG
Bioorg Med Chem Lett; 2015 Mar; 25(6):1269-73. PubMed ID: 25677656
[TBL] [Abstract][Full Text] [Related]
9. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.
Manjunatha UH; Boshoff H; Dowd CS; Zhang L; Albert TJ; Norton JE; Daniels L; Dick T; Pang SS; Barry CE
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):431-6. PubMed ID: 16387854
[TBL] [Abstract][Full Text] [Related]
10. Nitroimidazoles for the treatment of TB: past, present and future.
Mukherjee T; Boshoff H
Future Med Chem; 2011 Sep; 3(11):1427-54. PubMed ID: 21879846
[TBL] [Abstract][Full Text] [Related]
11. Targeting Phenotypically Tolerant Mycobacterium tuberculosis.
Gold B; Nathan C
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28233509
[TBL] [Abstract][Full Text] [Related]
12. Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway.
Karabanovich G; Fabiánová V; Vocat A; Dušek J; Valášková L; Stolaříková J; Kitson RRA; Pávek P; Vávrová K; Djaout K; Mikušová K; Baulard AR; Cole ST; Korduláková J; Roh J
J Med Chem; 2024 Jan; 67(1):81-109. PubMed ID: 38157261
[TBL] [Abstract][Full Text] [Related]
13. Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular
Ahmed S; Chowdhury S; Gomez J; Hung DT; Parish T
ACS Infect Dis; 2023 Oct; 9(10):1981-1992. PubMed ID: 37708378
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and
Eke IE; Williams JT; Haiderer ER; Albrecht VJ; Murdoch HM; Abdalla BJ; Abramovitch RB
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0047423. PubMed ID: 37610224
[TBL] [Abstract][Full Text] [Related]
15. The Role of Nitroreductases in Resistance to Nitroimidazoles.
Thomas C; Gwenin CD
Biology (Basel); 2021 May; 10(5):. PubMed ID: 34062712
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Tasneen R; Williams K; Amoabeng O; Minkowski A; Mdluli KE; Upton AM; Nuermberger EL
Antimicrob Agents Chemother; 2015 Jan; 59(1):129-35. PubMed ID: 25331697
[TBL] [Abstract][Full Text] [Related]
18. Energy metabolism and drug efflux in Mycobacterium tuberculosis.
Black PA; Warren RM; Louw GE; van Helden PD; Victor TC; Kana BD
Antimicrob Agents Chemother; 2014 May; 58(5):2491-503. PubMed ID: 24614376
[TBL] [Abstract][Full Text] [Related]
19. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Tyagi S; Ammerman NC; Li SY; Adamson J; Converse PJ; Swanson RV; Almeida DV; Grosset JH
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):869-74. PubMed ID: 25561537
[TBL] [Abstract][Full Text] [Related]
20. Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization.
Eedara BB; Fan C; Sinha S; Khadka P; Das SC
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
